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Abstract: Clinical studies indicate the potential of bronchoscopic thermal vapor ablation to 
result in clinically relevant improvements in severe chronic obstructive pulmonary disease 
patients with upper lobe-predominant emphysema. However, the mechanisms by which vapor 
ablation results in lung volume reduction are not fully known. This study determined the 3-month 
safety and efficacy of vapor ablation in a canine model of emphysema and described the histo-
pathological changes in the lung. The cranial lobes of papain-exposed dogs were treated with a 
vapor dose of ten calories per gram of lung tissue (n = 8) or were sham treated (n = 3). Safety 
was monitored peri- and postoperatively for 3 months. Animals were then sacrificed, estimates 
of lung volume reduction performed, and the lungs processed for histology. Vapor ablation was 
associated with an average of 20% volume reduction of the treated lobes and an absence of 
serious adverse events. The amount of lobar volume reduction was correlated with the amount 
of fibrosis and atelectasis in the treated lobe. Bronchoscopic thermal vapor ablation at a dose 
of 10 cal/g results in lobar volume reduction associated with remodeling of the targeted tissue 
characterized by mature collagen formation in the absence of major adverse events.
Keywords: animal models, chronic obstructive pulmonary disease, bronchoscopy, lung volume 
reduction
Introduction
The NETT (National Emphysema Treatment Trial), a randomized controlled trial 
of medical management compared with lung volume reduction surgery (LVRS), 
demonstrated that LVRS in patients with emphysema, particularly those with upper 
lobe-predominant disease, improves lung function, exercise tolerance, and health-
related quality of life and can improve survival in a subset of patients.1,2 However, 
the procedure is associated with a short-term increase in mortality and often leads to 
complications requiring prolonged hospitalization. Therefore, an alternative treatment 
to LVRS that is associated with an improved safety profile has been sought. Various 
minimally invasive bronchoscopic approaches are being investigated as a means to 
induce sustained lung volume reduction.3–9
Bronchoscopic thermal vapor ablation (BTVA) uses heated water vapor to pro-
duce lung volume reduction. The system consists of a reusable vapor generator with a 
disposable vapor catheter, used to deliver heated water vapor through a bronchoscope 
channel to targeted upper lobe emphysematous lung regions. Clinical studies indicate 
the potential of BTVA to induce clinically relevant improvements in severe to very 
severe COPD patients with upper lobe-predominant emphysema.10,11
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The feasibility of using water vapor to induce lung 
  volume reduction in an animal model was first described by 
Emery et al.12 They performed a dose-ranging study in dogs, 
which demonstrated the effectiveness of BTVA in reducing 
lung volume. However, the mechanisms by which BTVA 
treatment results in lung volume reduction were not explored. 
As that study was conducted in healthy dogs, the efficacy 
and safety of BTVA when applied to the emphysematous 
lung was unknown.
The objectives of the current study were two-fold: (1) to 
determine the 3-month safety and efficacy profile of BTVA 
in an animal model of emphysema, the papain-exposed dog, 
using a clinically relevant dose (10 cal/g), and (2) to describe 
the histopathological changes induced by BTVA. Part of this 
work was previously published in abstract form.13
Methods
All procedures were reviewed and approved by the Institu-
tional Animal Care and Use Committee of American Pre-
clinical Sciences (Coon Rapids, MN). Refer to Appendix 1 
for additional details of methods used.
Study procedures
Eleven adult mongrel dogs (mean wt = 20.9 kg), previously 
exposed to papain by inhalation, were assigned to either a 
BTVA treatment (n = 8) or a sham treatment group (n = 3). 
Prior to treatment, measurements of vital signs and func-
tional residual capacity (FRC)14 were taken; blood work was 
obtained for measurement of hematology, biochemistry, and 
tissue injury parameters; and computed tomography (CT) 
scans were taken of the chest and brain.
The BTVA procedure was then performed in anesthe-
tized, intubated animals. A vapor catheter, connected to a 
vapor generator, was introduced through a bronchoscope 
into the airway of the lung segment selected for treatment, 
where an occlusion balloon was then inflated and the pre-
determined vapor dose (10 cal/g of lung tissue) delivered to 
the targeted lung segments. A total of three segments in the 
upper lobes were targeted for treatment: two segments in the 
right cranial lobe and one segment in the left cranial lobe. 
The order of treatment was randomized. Sham treatment 
consisted of placement of the catheter and balloon inflation 
for a time similar to that required to deliver a vapor dose 
of 10 cal/g. Heart rate (HR), mean arterial blood pressure 
(MAP), and arterial oxygen saturation (SaO2) were monitored 
immediately prior to and after BTVA or sham treatments. 
After the three vapor treatments were delivered, the animal 
was recovered from anesthesia and returned to housing.
Postoperative assessments consisted of blood work 
(postoperative Days 1, 3, 7, 30, and 90), clinical observa-
tions (daily from Day 1 to Day 10 at a minimum), FRC 
measurements, and chest and brain CTs at 30 and 90 days. 
At ∼90 days posttreatment the animals were euthanized,   
lungs removed, and visual estimates of lobar volume reduc-
tion performed, and the lungs were processed for histological 
analysis.
The lung tissue slides were assessed for fibrosis, inflam-
mation, tissue damage, and atelectasis. Fibrosis was further 
defined according to the maturity of the response (immature 
and mature granulation tissue versus mature fibrosis) as well 
as the distribution. Inflammation was further defined as acute, 
chronic with ongoing tissue damage and repair, or chronic 
without evidence of ongoing tissue damage and repair. 
The proportion of slides with a given finding, expressed as 
a percentage of the total number of slides examined, was 
reported for each lobe. The average severity of fibrosis and 
atelectasis for the combined treated left and right lobes was 
calculated for each animal and correlated with the amount 
of lobar volume reduction observed at necropsy.
Statistical analysis
Paired t-tests were used to compare pretreatment with post-
treatment values, and unpaired t-tests were used to compare 
BTVA-treated and sham-treated groups. Pearson product 
moment correlations were used to assess the association 
between lobar lung volume reduction and the histological 
findings of fibrosis and atelectasis. A significance value of 
P , 0.05 was used.
Results
The papain exposure protocol resulted in a 35% ± 19% 
increase in FRC, measured just prior to treatment relative to 
FRC measured just prior to the first papain exposure.
All animals were treated with BTVA successfully without 
any device malfunction or perioperative adverse events. The 
average vapor delivery time per segment was 4.1 seconds 
(range 2.8–7.4 seconds). The average vapor delivery time 
total per animal was 12.3 seconds (range 10.7–16.4   seconds), 
resulting in a delivery of 479 ± 75 calories of energy per 
animal.
Acute cardiovascular effects
Pre- and posttreatment electrocardiograms were obtained 
in six of eight BTVA-treated dogs and three of three 
sham-treated dogs. All dogs maintained sinus rhythms, 
and no arrhythmias were observed. With the exception of   
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a   significant decrease in RR interval immediately after the 
third treatment in the BTVA dogs (634 ms at pretreatment 
versus 565 ms posttreatment, P = 0.049), no significant 
change in any other electrocardiogram interval was observed 
in BTVA- or sham-treated dogs (data not shown).
SaO2 was in a normal range (.90%) at pretreatment 
and posttreatment for all animals with the exception of one   
sham-treated dog with a posttreatment SaO2 of 88%. A sta-
tistically significant decrease in SaO2 was evident after the 
third vapor treatment in the BTVA group (mean decrease in 
SaO2 = 3.5%, P = 0.006) (Figure 1A). The average decrease 
in SaO2 after the third treatment was similar in the sham-
treated group (mean decrease in SaO2 = 3%), although this 
decrease was not statistically significant.
HR data were available for six of eight BTVA-treated 
dogs and three of three sham-treated dogs. No significant dif-
ference in HR between pre- and posttreatment was observed 
for BTVA- or sham-treated groups (Figure 1B). MAP data 
were available for six of eight BTVA-treated dogs and three 
of three sham-treated dogs. A significant increase in MAP 
(mean increase = 8 mmHg) between pre- and posttreatment 
was observed in the BTVA group but not the sham-treated 
group (Figure 1C).
Clinical observations
Clinical observations in BTVA-treated dogs were mild in 
nature and lasted, on average, 3 days or less (Table 1). The 
most frequent observations after BTVA treatment were 
  sputum production and coughing lasting, on average, 3 days 
and 2 days, respectively. Other observations consisted 
of abnormal lung auscultation and above normal body 
  temperature, both of which were present for an average of 
1 day post-BTVA treatment. Sham-treated dogs displayed 
sputum production for an average of 1 day after treatment.
Clinical pathology
A transient increase in white blood cells was observed 
after BTVA treatment, which peaked at 17.4 × 109 on Day 
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Figure 1 Acute cardiovascular response to bronchoscopic thermal vapor ablation (BTVA). (A) arterial oxygen saturation (SaO2) measured just prior to first treatment 
(pretreatment) and immediately after the third vapor treatment (posttreatment); n = 8 BTVA, n = 3 sham. (B) Heart rate measured just prior to and immediately after each 
treatment. Data were not analyzable in two BTVA-treated dogs. Data for all individual treatments were pooled for each animal; n = 18 BTVA, n = 9 sham. (C) Mean arterial 
pressure measured just prior to and immediately after the first and second vapor treatments. Data were not analyzable in two BTVA-treated dogs. Data for all individual 
treatments were pooled for each animal; n = 11 BTVA, n = 8 sham.
Note: *Significantly different from pretreatment, P , 0.05.
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7, which would be considered slightly above normal range 
(Table 2). Modest elevations in generalized markers of   tissue 
injury (creatine kinase, lactate dehydrogenase) were also 
observed after BTVA treatment, although the mean values   
posttreatment were not considered outside of the normal 
range for dogs. Changes in other clinical pathology param-
eters measured were mild and transient.
CT findings
Review of brain and chest CTs taken 30 days and 90 days 
posttreatment showed no evidence of stroke or pneumothorax 
in either BTVA- or sham-treated animals (Table 3). Evidence 
of consolidation in the left and right cranial lobes was appar-
ent at 30 days and 90 days in the BTVA-treated dogs but not 
in the sham-treated dogs.
Volume loss in the treated cranial lobes after treatment 
was apparent by CT. Representative examples of images 
taken pre- and 3 months post-BTVA are given in Figure 2.
Lobar volume reduction  
and gross pathology
Lobar volume reduction was observed in 100% of the lobes 
treated with vapor. The average amount of visual lobar 
volume reduction in the treated right and left upper lobes 
was 20% ± 8% and 19% ± 15%, respectively. An example 
of lobar volume reduction 3 months after BTVA treatment 
is shown in Figure 3.
Functional residual capacity 
measurements
FRC measurements made at 1 month and 3 months post-
treatment showed no difference between the sham- and 
BTVA-treated groups.
Histopathology
Treated cranial lobes
A total of 805 slides from the treated right and left cranial 
lobes (565 slides from BTVA-treated dogs; 240 from sham-
treated dogs) were assessed for fibrotic and inflammatory 
findings. As opposed to the cranial lobes of sham-treated 
dogs, where airway and parenchymal fibrosis were absent, 
findings of airway and parenchymal fibrosis were frequent 
in the cranial lobes of BTVA-treated animals. A total of 31% 
of slides from the cranial lobes of BTVA-treated dogs had 
evidence of peribronchial fibrosis, 27% had evidence of peri-
bronchiolar fibrosis, and 20% had evidence of parenchymal 
fibrosis (Table 4). The fibrosis observed in the BTVA-treated 
lobes was almost exclusively mature collagen; only one 
finding of mature granulation tissue in a BTVA-treated lobe 
was reported, representing 0.2% of the total slides assessed. 
A small proportion of slides in both treatment groups had 
evidence of alveolar septal fibrosis (3% from BTVA-treated 
lobes; 4% from sham-treated lobes), suggesting a background 
level of alveolar septal fibrosis possibly related to the papain 
exposure.
Acute inflammation was not observed in either the 
BTVA-treated or sham-treated lobes at 90 days post-
treatment (Table 5). A higher proportion of slides from the 
BTVA-treated lobes had observations of macrophages or 
hemosiderophages in alveolar airspaces/septa compared 
Table 1 Clinical observations in first 10 days postbronchoscopic 
thermal vapor ablation (BTVA) or sham treatment
Clinical observation Duration (days)
BTVA (n = 8) Sham (n = 3)
Coughing 2 ± 2 0 ± 1
Sputum 3 ± 2 1 ± 1
Abnormal attitude/behavior 0 ± 1 0 ± 0
Abnormal lung auscultation 1 ± 1 0 ± 1
Above normal body temperature 1 ± 1 0 ± 0
Abnormal arterial oxygen saturation 0 ± 0 0 ± 0
Death 0 0
Note: Data are presented as mean ± standard deviation.
Table 2 Blood markers of inflammation and tissue injury after BTVA or sham treatment
Parameter Group Baseline Day 1 Day 3 Day 7 Day 30 Day 90
WBC (×109) BTVA 5.9 ± 1.6 15.8 ± 5.4 12.7 ± 4.6 17.4 ± 7.1 7.8 ± 3.9 7.0 ± 1.5
Sham 6.9 ± 1.3 11.6 ± 2.3 10.3 ± 1.7   9.0 ± 1.4 6.6 ± 0.3 6.8 ± 2.2
CK (U/L) BTVA 146 ± 115  281 ± 161  263 ± 328  159 ± 44
Sham 190 ± 159  177 ± 14  133 ± 74  110 ± 26
LDH (U/L) BTVA   48 ± 24  153 ± 74  101 ± 42  142 ± 57
Sham   80 ± 18  111 ± 62  104 ± 65   77 ± 49
Note: Values are mean ± standard deviation.
Abbreviations: BTVA, bronchoscopic thermal vapor ablation; CK, creatine kinase; LDH, lactate dehydrogenase (not measured at Day 30 or Day 90); WBC, white blood cells.
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Table 3 Chest and brain CT findings at 30 and 90 days posttreatment
CT finding Number of animals with findings
BTVA (n = 8) Sham (n = 3)
30 days 90 days 30 days 90 days
Stroke 0 0 0 0
Pneumothorax 0 0 0 0
Consolidation, right cranial lobe 8 2 0 0
Consolidation, left cranial lobe 3 4 0 0
Abbreviations: BTVA, bronchoscopic thermal vapor ablation; CT, computed tomography.
Pre-BTVA 3 mo post-BTVA
R cranial
lobe
R cranial
lobe
L cranial
lobe
L cranial
lobe
Figure  2  Axial  computed  tomography  images  of  the  cranial  lobes  before  and 
3 months after bronchoscopic thermal vapor ablation (BTVA) treatment.
AB
Figure 3 Example of lobar volume reduction 3 months after bronchoscopic thermal 
vapor ablation treatment. (A) Twenty-eight percent reduction of the right cranial 
lobe. (B) Thirteen percent reduction of the left cranial lobe. The comparison lung on 
the right of each image is a dried lung from a similar-sized untreated dog.
Table 4   Fibrosis  in  bronchoscopic  thermal  vapor  ablation 
(BTVA)- and sham-treated cranial lobes 90 days after treatment 
as assessed by histology
Finding Percentage of slides from treated  
cranial lobes with findings
BTVA 
(n = 8; 565 slides)
Sham 
(n = 3; 240 slides)
Immature granulation  
tissue
0 0
Mature granulation  
tissue
0.2 0
Mature collagen
  Peribronchial 31 0
  Peribronchiolar 27 0
  Parenchymal 20 0
  Alveolar septal 3 4
with sham-treated lobes (28% versus 7% for macrophages, 
18%   versus 1% for   hemosiderophages). However, these 
infiltrates were not associated with ongoing tissue injury/repair. 
No pleural inflammation was noted in either treatment group.
A representative example of histopathology from the 
cranial lobe of a BTVA-treated dog is shown in Figure 4. 
A linear band of mature fibrosis can be seen radiating out 
toward the parenchyma from a bronchus, which is also 
encircled by mature fibrosis. Regions of atelectasis are seen 
adjacent to the fibrosis.
Untreated middle and caudal lobes
Fibrosis or inflammation was infrequent in the untreated middle 
and lower lobes of dogs in the BTVA group. In the BTVA-
treated group, single observations (0.8% of slides reviewed) of 
peribronchial and parenchymal fibrosis, chronic inflammatory, 
and mixed inflammatory infiltrates were noted, as well as four 
observations (3.2% of slides reviewed) of macrophages within 
airspaces (Table 6). In the untreated lobes of sham-treated dogs, 
the only findings were of chronic inflammatory cell infiltrates 
observed in three slides (6% of slides reviewed).
Correlation between lobar volume reduction and 
histology findings of fibrosis and atelectasis
Significant correlations were found between the amount of 
parenchymal fibrosis and atelectasis observed histologically 
in the treated lobes and the estimated lobar volume reduction 
observed grossly (P , 0.001 and P = 0.002 for parenchymal 
fibrosis and atelectasis, respectively) (Table 7). No correla-
tion was observed between the amount of peribronchiolar or 
peribronchial fibrosis and lobar volume reduction.
Discussion
BTVA represents a treatment modality that can provide mean-
ingful benefits for patients with severe emphysema. Animal 
studies are needed to elucidate the histopathologic under-
standing of the mechanism of action and the safety of BTVA. 
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Table 5 Inflammation in bronchoscopic thermal vapor ablation (BTVA)- and sham-treated cranial lobes 90 days after treatment as 
assessed by histology
Finding Percentage of slides from treated cranial lobes  
with findings
BTVA 
(n = 8; 565 slides)
Sham 
(n = 3; 240 slides)
Acute inflammation 0 0
Chronic inflammation with ongoing tissue damage and repair 0.2 0
Chronic inflammation without ongoing tissue damage and repair 
  Chronic inflammatory cell infiltratesa 
  Mixed inflammatory infiltrate 
  Macrophages within alveolar air spaces 
  Alveolar septal hemosiderophages
 
6 
5 
28 
18
 
10 
3 
7 
1
Pleuritis 0 0
Vascular leakage, edema, hyaline membranes 0 0
Note: aInfiltrates around small venules in alveolar septa without necrosis or tissue destruction.
Figure 4 Histopathology example from a bronchoscopic thermal vapor ablation-
treated animal. 
Notes: Black arrow: collapsed bronchus encircled by mature fibrosis. Red arrow: 
dense  band  of  mature  collagen  extending  from  treated  bronchus  to  pleura. 
Black circle and box: areas of subpleural atelectasis at the ends of linear fibrosis. 
1× Masson’s trichrome.
In the papain-exposed canine model of emphysema, BTVA 
at a vapor dose of 10 cal/g was associated with an average 
of 20% volume reduction of the treated lobes; no detrimental 
acute cardiovascular effects; no pneumothorax, respiratory 
distress, stroke, or death; and resolution of inflammatory 
processes by 3 months.
This is the first study reporting the effects of vapor abla-
tion in an animal model of emphysema. Compared with 
normal lung tissue, emphysematous lungs have character-
istics that may possibly affect the safety and efficacy of 
treatment, such as differences in perfusion, altered tissue 
composition, and tissue to air ratios. The distribution of 
emphysema in the papain-treated canine, which has been 
described as panlobular and homogeneous,15,16 does differ 
from that of the target clinical population (centrilobular and 
upper lobe predominant), thus is a limitation of this study. 
However, this study does demonstrate that a therapeutically 
relevant BTVA dose of 10 cal/g can produce lobar volume 
reduction in the absence of serious adverse events in a lung 
with emphysema-like changes.
The vapor dose used in this study (10 cal/g) was equiva-
lent to approximately 1.8 cal/t, which was between the low 
(∼1 cal/mL) and medium (∼4 cal/mL) doses reported by 
Emery et al.12 Similar to the current study, Emery et al demon-
strated that BTVA treatment induces lung volume reduction. 
Emery et al also described one pneumothorax-related death 
and possible heat-induced injury to adjacent tissues; however, 
those events occurred in dogs treated with medium or high 
(∼8 cal/mL) doses, which are well above the clinical doses 
used in humans. The current study is consistent with findings 
from a trial in 44 emphysematous patients who received a 
vapor dose of 10 cal/g, noting that the treatment was well 
tolerated and had an acceptable safety profile.11 It should be 
noted that, as of yet, clinical use of BTVA has been limited 
to unilateral treatment only.
The regional volume reduction apparent upon visual 
examination of the upper lobes from the BTVA-treated 
canines was not reflected in FRC as measured by helium 
dilution. It is likely that the limitations of helium dilution in 
the measurement of trapped gas as well as the papain-induced 
model (predominantly homogeneous emphysema) explain 
the discrepancy between the clear visual reduction in lobar 
volume and the measurement of FRC.
The mechanism of action for lung volume reduction after 
BTVA treatment has not been fully understood. It is expected 
that the initial thermal response to the treated airways and 
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parenchyma results in a localized inflammatory response. 
This initial inflammatory response is followed by a healing 
process, which leads to permanent remodeling of the lung 
tissue. Although this study does not address early inflamma-
tory events, the histology findings 3 months after treatment 
establish that fibrosis (in particular, parenchymal fibrosis) and 
distal atelectasis in the treated regions are important effects 
of vapor ablation. Scar tissue formed during the remodeling 
process replaces diseased, hyperinflated lung parenchyma. 
Because the scar tissue occupies a much smaller volume from 
which it derives, the process reduces the air and tissue volume 
of the treated lobe. Fibrosis of airways likely contributes 
to the atelectasis as airway narrowing/occlusion prevents 
airflow into distal airspaces. Both parenchymal fibrosis and 
atelectasis in the treated lobes correlated significantly with 
lobar volume reduction.
Although an initial inflammatory response in the treated 
regions is an expected response to treatment, a prolonged or 
chronic inflammatory response after treatment would not be 
desirable. This study shows that the inflammatory process is 
resolved by 3 months after treatment. At this time point, the 
treatment-induced effects in the lung are characterized by 
mature fibrosis and remodeling with associated atelectasis 
in the absence of inflammation. Further studies detailing the 
time course of pathological processes in the lung in response 
to BTVA using additional techniques such as immunostain-
ing would be of benefit.
In this study, vapor ablation did not appear to affect 
areas of the lung other than those targeted for treatment, as 
the untreated middle or caudal lobes had negligible findings 
of fibrosis, inflammation, or tissue injury 3 months after 
treatment. Collateral ventilation between lobes could be one 
potential mechanism by which vapor could have effects in 
regions of the lung other than within the targeted segments. 
Given that the canine lung has a larger degree of collateral 
ventilation than does the human lung,17 this study does not 
support this mechanism as a possible concern.
Conclusion
In conclusion, in a canine model of emphysema, BTVA at 
a vapor dose of 10 cal/g results in lobar volume reduction 
  associated with remodeling of the targeted tissue   characterized 
by mature collagen formation without acute or chronic 
inflammation in the absence of major adverse events. The canine 
model provides objective data regarding the   histopathologic 
mechanism of action of volume reduction and subsequent 
favorable clinical outcomes observed in human trials.
Table 6 Histopathology findings in untreated middle and caudal lobes 90 days after treatment
Finding Percentage of slides from untreated middle  
and caudal lobes with findings
BTVA 
(n = 8; 125 slides)
Sham 
(n = 3; 50 slides)
granulation tissue 0 0
Mature collagen 
  Peribronchial 
  Peribronchiolar 
  Parenchymal 
  Alveolar septal
 
0.8 
0 
0.8 
0
 
0 
0 
0 
0
Acute inflammation 0 0
Chronic inflammation 0 0
Chronic inflammation without ongoing tissue damage and repair 
  Chronic inflammatory cell infiltrates 
  Mixed inflammatory infiltrate 
  Macrophages within alveolar air spaces 
  Alveolar septal hemosiderophages
 
0.8 
0.8 
3.2 
0
 
6.0 
0 
0 
0
Pleuritis 0 0
Vascular leakage, edema, hyaline membranes 0 0
Abbreviation: BTVA, bronchoscopic thermal vapor ablation.
Table 7 Correlations between histology findings of fibrosis and 
atelectasis and lobar volume reduction in bronchoscopic thermal 
vapor ablation-treated cranial lobes
Parameter Correlation with lobar   
volume reduction
r-value P-value
Average parenchymal fibrosis score 0.80 ,0.001
Average peribronchiolar fibrosis score -0.005 0.984
Average peribronchial fibrosis score 0.159 0.556
Average amount of in vivo atelectasis 0.71 0.002
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Appendix 1: detailed study 
methodology
Methods
All procedures were reviewed and approved by the Insti-
tutional Animal Care and Use Committee of American 
Preclinical Sciences (Coon Rapids, MN). Unless otherwise 
stated, all averaged values are presented as mean ± standard 
deviation.
Animal model
In order to induce emphysema-like changes in the lungs, 
eleven adult mongrel dogs (mean wt = 20.9 kg) were exposed 
twice to aerosolized papain (3 mL of a 4% solution) via 
endotracheal tube while under anesthesia.1 The two papain 
exposures were separated by 7 days. Just prior to the first 
exposure, functional residual capacity (FRC) was measured, 
as described in this appendix.
Study design
The papain-exposed dogs were assigned to either a treat-
ment group (bilateral BTVA treatment; n = 8) or a sham 
group (bilateral sham treatment; n = 3). The BTVA or sham 
procedure was performed 74–79 days after the last papain 
exposure.
Prior to treatment, baseline measurements (vital signs, 
computed tomography [CT] scans of the chest and brain, 
blood work [hematology, biochemisty, coagulation, and 
tissue injury parameters], and FRC) were obtained. The 
animals then underwent bilateral BTVA or sham treatment 
of the upper lobes. Perioperative measurements of heart rate 
(HR), arterial blood pressure, and arterial oxygen saturation 
(SaO2) were monitored immediately prior to and after BTVA 
or sham treatments. Postoperative assessments consisted of 
blood work (postoperative Days 1, 3, 7, 30, and 90), clinical 
observations (daily from Day 1 to Day 10), and chest and 
brain CTs at Day 30 and Day 90. At ∼90 days posttreatment, 
the animals were euthanized, lungs removed, and visual 
estimates of lobar volume reduction performed, and then the 
lungs were processed for histological analysis.
Preprocedural animal preparation and 
functional residual capacity measurement
Animals were anesthetized with isoflurane in 100% O2 and 
then intubated. FRC was measured by the helium dilution 
method.2 The FRC measurement was repeated three times and 
the average of the three measurements was used to determine 
the BTVA delivery time (see Bronchoscopic thermal vapor 
ablation treatment).
Bronchoscopic thermal vapor ablation 
treatment
The bronchoscopic thermal vapor ablation (BTVA) system 
comprises a vapor generator and a vapor catheter. The vapor 
generator is an electronically controlled pressure vessel that 
generates and delivers precise amounts of energy (heated 
vapor) through the vapor catheter and into a targeted lung 
segment. The vapor catheter is composed of a flexible shaft 
and occlusion balloon located at the distal end. The BTVA 
procedure was performed in intubated animals under general 
anesthesia. During the procedure, the vapor catheter was intro-
duced through the bronchoscope into the airway of the lung 
segment selected for treatment, where an occlusion balloon 
was then inflated and the predetermined vapor dose (10 cal/g 
of lung tissue) delivered to the targeted lung segments. A total 
of three segments in the cranial lobes were targeted for treat-
ment: two segments in the right cranial lobe (the first dorsal 
branch in the right cranial [RB1D1] and the branch distal to 
the second dorsal branch [RB1-distal]) and one segment in 
the left cranial lobe (the branch distal to the first dorsal branch 
[LB1-distal]). The order of treatment was randomized.
The time of vapor delivery was based on the estimation of 
segmental tissue mass for each individual dog.   Preliminary 
studies were performed using canine lung casts to   determine 
the percentage of total measured air volume (as   estimated 
by FRC) represented by each cranial lobe segment 
(RB1D1 = 5% of FRC, RB1-distal = 9.3% of FRC, LB1-
distal = 6.4% of FRC). Segmental air volume was estimated 
using the appropriate percentage of FRC, then segmental 
mass was estimated based on density of the upper lobe region 
as calculated for each dog from chest CTs taken an average of 
23 days (range 20–28 days) prior to treatment. A single value 
of lung density, in g/L, was calculated from representative 
slices of the left and right cranial lobes using the following 
relationship: density = lung attenuation in Hounsfield units 
(HU) + 1000. The time required to deliver a dose of 10 cal/g 
was then calculated for each segment based on the segmental 
mass and the time/energy relationship of the generator used. 
Sham treatment consisted of placement of the catheter and 
balloon inflation for a time similar to that required to deliver 
a vapor dose of 10 cal/g.
After the three vapor treatments were delivered, the 
animal was recovered from anesthesia and returned to its 
housing.
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Assessment of acute cardiovascular 
effects
Blood pressure, as measured by an indwelling femoral arte-
rial catheter, and electrocardiography (ECG) were measured 
for 30 seconds before and after each of three successive 
treatments. The average heart rate and mean arterial pres-
sure (MAP) were calculated over each 30-second period. In 
addition, ECG recordings were qualitatively assessed for 
rhythm, and one representative ECG complex per 30-second 
recording was quantitatively analyzed for RR, PQ, QRS, QT, 
and corrected QT (QTc) intervals. The QTc intervals were 
calculated using the methods of Fridericia.3
An arterial blood gas sample was taken from the femoral 
artery just prior to treatment of the first segment (baseline) 
and within a minute of treatment of the third segment. The 
blood sample was immediately analyzed for SaO2.
Clinical observations
Clinical observations and vital signs (temperature, HR, 
  respiratory rate, peripheral oxygen saturation by pulse 
  oximeter) were documented daily by trained animal care 
personnel for at least 10 days posttreatment.
Computed tomography assessment
CT scans of the chest and brain were performed at pretreat-
ment, 30 days (±7 days) posttreatment and at the time of 
  sacrifice (90 ± 7 days) using a mobile CT unit (Siemens 
  Emotion 6; Munich, Germany). Lung scans were performed 
at both end-inspiration and end-expiration. The CT images 
were   qualitatively evaluated by a trained radiologist. The 
brain scan was assessed for evidence of embolic stroke, and 
the chest CT scan was assessed for evidence of pneumothorax 
and consolidation in the treated or untreated lobes.
Clinical pathology
Blood samples were taken at pretreatment (Day 0) and at 
Days 1, 3, 7, and 30 (±7 days) posttreatment and the day   
of sacrifice (90 ± 7 days). In addition to hematology and 
serum biochemistry, tissue injury markers (total creatine 
kinase and lactate dehydrogenase) were also measured at 
Days 0, 1, 3, and 7.
Assessment of lobar volume changes
Approximately 90 days after treatment, the animals were 
euthanized by exsanguination while under general anesthesia. 
At necropsy, the lungs were removed and inflated with air 
to a pressure of 20–30 cm H2O. Two observers, blinded 
to the treatment condition, visually scored the amount of 
right and left cranial lobar volume reduction observed in 
the treated lungs in relationship to reference lungs from 
a normal untreated dog of similar size whose lungs had 
been dried while at a similar inflation pressure. The lobar 
volume reduction of the right cranial and left cranial lobes 
was expressed as percentage reduction. The average score of 
the two reviewers was calculated and rounded to the nearest 
whole number.
Histopathology assessment
The lungs were processed for histological examination by 
tracheal instillation of 10% buffered formalin and then sub-
merged in formalin for a minimum of 24 hours. The lungs 
were then serially sliced at ∼5 mm intervals. For the treated 
right and left cranial lobes, every other slice was sampled in 
its entirety and placed in cassettes for histologic processing. 
For the untreated lobes (left and right middle, left and right 
caudal), only the largest slice was sampled and placed in 
cassettes for processing. Tissue cassettes were embedded in 
paraffin, sectioned at ∼5 µm, and stained with hematoxylin-
eosin and Masson’s trichrome.
The tissue slides were assessed for three categories 
of findings: fibrosis, inflammation, and tissue damage. 
  Fibrosis was further defined according to the maturity of the 
response (immature and mature granulation   tissue   versus 
mature fibrosis) as well as the distribution (parenchymal, 
peribronchial, peribronchiolar, and alveolar septal). 
  Inflammation was further defined as acute (numerous 
viable or degranulated neutrophils within alveolar air 
spaces or septa with small amounts of necrotic or pyknotic 
debris), chronic with ongoing tissue damage and repair 
(influx of mononuclear cells, including macrophages, 
lymphocytes, and plasma cells, and small numbers of 
neutrophils), or chronic without evidence of ongoing tissue 
damage and repair (macrophages, mixed inflammation of 
  predominantly macrophages with rare to few neutrophils, 
or hemosiderophages in the airspaces/alveolar septa). 
Tissue damage was assessed according to evidence of 
vascular leakage, edema fluid, or fibrin accumulation. The 
proportion of slides with a given finding, expressed as a 
percentage of the total number of slides examined, was 
reported for each lobe.
Correlation between fibrosis, alveolar 
collapse, and lobar volume reduction
Each finding of fibrosis (peribronchial, peribronchiolar, and 
parenchymal) was assigned a qualitative score based on a 
combination of the amount and density of fibrosis present 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
30
Tuck et alInternational Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-copd-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2012:7
(1 = minimal, 2 = mild, 3 = moderate, and 4 = severe). For 
each right and left cranial lobe from the BTVA-treated dogs, 
the average severity score was calculated across all slides 
from the lobe. The average severity score for peribronchial, 
peribronchiolar, and parenchymal fibrosis for each animal 
was correlated with the amount of lobar volume reduction 
observed at the time of necropsy. For this analysis, right and 
left lobes were combined.
Each slide was also assessed for in vivo atelectasis, defined 
as incomplete expansion of alveolar air space, which most 
likely occurred in vivo (as opposed to during tissue process-
ing). The atelectasis was scored according to the approximated 
percentage of the lung tissue involved on each slide, in incre-
ments of 5%. If present but in a very low amount (ie, ,5%), 
a score of 2.5% was recorded. The average amount of in vivo 
atelectasis for each animal was correlated with the amount of 
lobar volume reduction observed at the time of necropsy. For 
this analysis, right and left lobes were combined.
Statistical analysis
Paired t-tests were used to compare pretreatment to post-
treatment values for ECG intervals (PR, QRS, RR, QT, QTc), 
SaO2, HR, and MAP. An unpaired t-test was used to compare 
lobar volume reduction between BTVA-treated and sham-
treated groups. Pearson product moment correlations were 
used to detect the presence of an association between the 
amount of lobar lung volume reduction and the histological 
findings of fibrosis and in vivo atelectasis. A significance 
value of P , 0.05 was used.
References
1.  Rosenthal FS. Aerosol probes of lung injury in a 28-wk longitudinal 
study of mild experimental emphysema in dogs. J Appl Physiol. 
1999;86:725–731.
2.  Anthonisen NR. Tests of mechanical function. In: Macklem PT, Mead J, 
editors. Handbook of physiology. The respiratory system, Section 3, 
Vol. III, Chapter 44. Bethesda, MD: American Physiological Society; 
1986:753–784.
3.  Fridericia LS. The duration of systole in an electrocardiogram in 
normal humans and patients with heart disease [Die systolendauer im 
elektrokarfiogramm bei normalen menchan und bei herzdranken]. Acta 
Med Scand. 1920;53:469–486. [German.]
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
31
BTVA in a canine model of emphysema